Clinical Trial Update: Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating SIRPant-M in participants with relapsed or refractory Non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• SIRPant-M

Snippet

Sponsor: SIRPant Immunotherapeutics, Inc. | Conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING